Titre : Commission d'évaluation du paiement à l'activité (USA)

Commission d'évaluation du paiement à l'activité (USA) : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Commission d'évaluation du paiement à l'activité (USA) : Questions médicales les plus fréquentes", "headline": "Commission d'évaluation du paiement à l'activité (USA) : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Commission d'évaluation du paiement à l'activité (USA) : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-22", "dateModified": "2025-04-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Commission d'évaluation du paiement à l'activité (USA)" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Système de paiements préétablis", "url": "https://questionsmedicales.fr/mesh/D011445", "about": { "@type": "MedicalCondition", "name": "Système de paiements préétablis", "code": { "@type": "MedicalCode", "code": "D011445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.219.521.710.305.200" } } }, "about": { "@type": "MedicalCondition", "name": "Commission d'évaluation du paiement à l'activité (USA)", "alternateName": "Prospective Payment Assessment Commission", "code": { "@type": "MedicalCode", "code": "D011444", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Patrícia Matos", "url": "https://questionsmedicales.fr/author/Patr%C3%ADcia%20Matos", "affiliation": { "@type": "Organization", "name": "School of Psychology, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal." } }, { "@type": "Person", "name": "Pedro B Albuquerque", "url": "https://questionsmedicales.fr/author/Pedro%20B%20Albuquerque", "affiliation": { "@type": "Organization", "name": "School of Psychology, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal." } }, { "@type": "Person", "name": "Jack Tsai", "url": "https://questionsmedicales.fr/author/Jack%20Tsai", "affiliation": { "@type": "Organization", "name": "School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA Jack.Tsai@uth.tmc.edu." } }, { "@type": "Person", "name": "Jeffrey Pearson", "url": "https://questionsmedicales.fr/author/Jeffrey%20Pearson", "affiliation": { "@type": "Organization", "name": "Arbor Research Collaborative for Health, Ann Arbor, Michigan; and." } }, { "@type": "Person", "name": "Chad Cogan", "url": "https://questionsmedicales.fr/author/Chad%20Cogan", "affiliation": { "@type": "Organization", "name": "Arbor Research Collaborative for Health, Ann Arbor, Michigan; and." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36651430", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/acb371205" } }, { "@type": "ScholarlyArticle", "name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36253300", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clgc.2022.09.007" } }, { "@type": "ScholarlyArticle", "name": "The mendelian randomized study revealed the association of prostatitis with prostate cancer risk.", "datePublished": "2024-10-20", "url": "https://questionsmedicales.fr/article/39428439", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-76355-4" } }, { "@type": "ScholarlyArticle", "name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.", "datePublished": "2023-05-26", "url": "https://questionsmedicales.fr/article/37271051", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cmpb.2023.107624" } }, { "@type": "ScholarlyArticle", "name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.", "datePublished": "2023-03-14", "url": "https://questionsmedicales.fr/article/36917412", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11255-023-03531-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Économie", "item": "https://questionsmedicales.fr/mesh/D004467" }, { "@type": "ListItem", "position": 4, "name": "Financement organisé", "item": "https://questionsmedicales.fr/mesh/D005381" }, { "@type": "ListItem", "position": 5, "name": "Remboursement par l'assurance maladie", "item": "https://questionsmedicales.fr/mesh/D007349" }, { "@type": "ListItem", "position": 6, "name": "Mécanismes de remboursement", "item": "https://questionsmedicales.fr/mesh/D012051" }, { "@type": "ListItem", "position": 7, "name": "Système de paiements préétablis", "item": "https://questionsmedicales.fr/mesh/D011445" }, { "@type": "ListItem", "position": 8, "name": "Commission d'évaluation du paiement à l'activité (USA)", "item": "https://questionsmedicales.fr/mesh/D011444" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Commission d'évaluation du paiement à l'activité (USA) - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Quel est le rôle de la Commission ?\nComment la Commission collecte-t-elle des données ?\nQuels types de soins sont évalués ?\nQui compose la Commission ?\nQuels critères sont utilisés pour l'évaluation ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Prostatic+Neoplasms&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Quels problèmes la Commission cherche-t-elle à résoudre ?\nComment la Commission évalue-t-elle l'accès aux soins ?\nQuels indicateurs de performance sont utilisés ?\nComment les résultats sont-ils communiqués ?\nQuels sont les impacts des recommandations de la Commission ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Prostatic+Neoplasms&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Quel est le rôle de la prévention dans l'évaluation ?\nComment la Commission promeut-elle la prévention ?\nQuels types de programmes sont soutenus ?\nComment la prévention impacte-t-elle les coûts ?\nQuels sont les obstacles à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Prostatic+Neoplasms&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Comment la Commission influence-t-elle les traitements ?\nQuels traitements sont souvent réévalués ?\nComment les hôpitaux s'adaptent-ils aux recommandations ?\nQuels sont les défis pour les hôpitaux ?\nComment la Commission évalue-t-elle l'efficacité des traitements ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Prostatic+Neoplasms&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Quelles complications sont surveillées par la Commission ?\nComment les complications affectent-elles les paiements ?\nQuels sont les impacts des complications sur les patients ?\nComment la Commission évalue-t-elle les complications ?\nQuelles mesures sont prises pour réduire les complications ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Prostatic+Neoplasms&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Quels facteurs de risque sont pris en compte ?\nComment les facteurs de risque influencent-ils les paiements ?\nQuels outils sont utilisés pour évaluer les risques ?\nComment la Commission aborde-t-elle les inégalités ?\nQuels sont les impacts des facteurs de risque sur les soins ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Prostatic+Neoplasms&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Quel est le rôle de la Commission ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elle évalue les systèmes de paiement pour améliorer l'efficacité des soins." } }, { "@type": "Question", "name": "Comment la Commission collecte-t-elle des données ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Elle utilise des études, des rapports et des données de facturation des hôpitaux." } }, { "@type": "Question", "name": "Quels types de soins sont évalués ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Tous les soins hospitaliers et ambulatoires sont pris en compte." } }, { "@type": "Question", "name": "Qui compose la Commission ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle est composée d'experts en santé, économistes et représentants des patients." } }, { "@type": "Question", "name": "Quels critères sont utilisés pour l'évaluation ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent la qualité des soins, les coûts et l'accès aux services." } }, { "@type": "Question", "name": "Quels problèmes la Commission cherche-t-elle à résoudre ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elle vise à réduire les inégalités d'accès et à améliorer la qualité des soins." } }, { "@type": "Question", "name": "Comment la Commission évalue-t-elle l'accès aux soins ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle analyse les données sur l'utilisation des services de santé par les populations." } }, { "@type": "Question", "name": "Quels indicateurs de performance sont utilisés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les indicateurs incluent les taux de réadmission et la satisfaction des patients." } }, { "@type": "Question", "name": "Comment les résultats sont-ils communiqués ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les résultats sont publiés dans des rapports accessibles au public et aux décideurs." } }, { "@type": "Question", "name": "Quels sont les impacts des recommandations de la Commission ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elles influencent les politiques de paiement et les pratiques de soins de santé." } }, { "@type": "Question", "name": "Quel est le rôle de la prévention dans l'évaluation ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est essentielle pour réduire les coûts et améliorer la santé publique." } }, { "@type": "Question", "name": "Comment la Commission promeut-elle la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elle recommande des programmes de prévention et des incitations financières." } }, { "@type": "Question", "name": "Quels types de programmes sont soutenus ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les programmes de vaccination et de dépistage sont souvent soutenus." } }, { "@type": "Question", "name": "Comment la prévention impacte-t-elle les coûts ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une meilleure prévention peut réduire les hospitalisations et les coûts à long terme." } }, { "@type": "Question", "name": "Quels sont les obstacles à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les obstacles incluent le manque de financement et l'accès limité aux services." } }, { "@type": "Question", "name": "Comment la Commission influence-t-elle les traitements ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle recommande des ajustements de paiement pour encourager des traitements efficaces." } }, { "@type": "Question", "name": "Quels traitements sont souvent réévalués ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements coûteux et ceux avec des résultats variables sont souvent réévalués." } }, { "@type": "Question", "name": "Comment les hôpitaux s'adaptent-ils aux recommandations ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Ils modifient leurs pratiques et protocoles pour répondre aux nouvelles directives." } }, { "@type": "Question", "name": "Quels sont les défis pour les hôpitaux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les hôpitaux doivent équilibrer coûts, qualité des soins et conformité aux recommandations." } }, { "@type": "Question", "name": "Comment la Commission évalue-t-elle l'efficacité des traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Elle analyse les résultats cliniques et les coûts associés à chaque traitement." } }, { "@type": "Question", "name": "Quelles complications sont surveillées par la Commission ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications liées aux soins hospitaliers, comme les infections nosocomiales." } }, { "@type": "Question", "name": "Comment les complications affectent-elles les paiements ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent entraîner des pénalités financières pour les hôpitaux." } }, { "@type": "Question", "name": "Quels sont les impacts des complications sur les patients ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent prolonger l'hospitalisation et affecter la récupération." } }, { "@type": "Question", "name": "Comment la Commission évalue-t-elle les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle analyse les taux de complications et les compare aux normes de soins." } }, { "@type": "Question", "name": "Quelles mesures sont prises pour réduire les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des protocoles de soins améliorés et des formations pour le personnel sont mises en place." } }, { "@type": "Question", "name": "Quels facteurs de risque sont pris en compte ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, les comorbidités et les conditions socio-économiques." } }, { "@type": "Question", "name": "Comment les facteurs de risque influencent-ils les paiements ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les hôpitaux reçoivent des ajustements de paiement basés sur les risques des patients." } }, { "@type": "Question", "name": "Quels outils sont utilisés pour évaluer les risques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des modèles statistiques et des bases de données de santé sont utilisés." } }, { "@type": "Question", "name": "Comment la Commission aborde-t-elle les inégalités ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Elle analyse les disparités d'accès et de résultats en fonction des facteurs de risque." } }, { "@type": "Question", "name": "Quels sont les impacts des facteurs de risque sur les soins ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent influencer la qualité des soins et les résultats pour les patients." } } ] } ] }

Sources (10000 au total)

Presence of HPV in prostate tissue from patients submitted to prostate biopsy.

Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat... Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus.... Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ... There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....

Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.

In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals.... This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ... It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high... As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...

Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.

With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di... We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ... An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve... This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...

Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.

To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n... The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit... In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ... A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...

Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.

Financial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk o... PCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated u... More than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk ... Aggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT....

Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?

Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga... Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu... Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114... The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...